FSR identified research developing, characterizing, or improving a sarcoidosis disease model as one of the critical investments needed in this space, and has designated significant funding toward the initiative. In Spring 2017, a grant amount, totaling $750,000, was awarded to five projects:
- Medical University of Vienna – Thomas Weichhart, PhD
Characterization and Improvement of a Novel Mouse Model that Spontaneously Develops Progressive Sarcoidosis by Chronic Activation of mTORC1
- Ohio State University – Elliott Crouser, MD, Larry Schlesinger, MD, Wolfgang Sadee, Dr.rer.nat, Peter White, PhD
A Novel In Vitro Human Granuloma Model of Sarcoidosis
- University of Freiburg – Peggy Engelhard, PhD, Gernot Zissel,PhD, Joachim Müller-Quernheim, MD, Marina A. Freudenberg, MD
Models for the investigations of the involvement of type I interferon (IFN-aB) in the pathogenesis of sarcoidosis
- University of Hull, York Medical School – Simon Hart, MBChB, PhD
Development and application of a multi-scale computational model of sarcoidosis to predict therapeutic approaches for non-self-resolving disease
- Yale School of Medicine – Erica Herzog, MD, PhD
Development of an ex vivo mimetic of the Sarcoidosis lung microenvironment
FSR is proud to host a symposium wherein awardees will share their findings and progress since 2017.
Details are provided below. Please RSVP via the form below and add this event to your calendar.
Contact FSR’s Director of Research Programs, Noopur Singh, at email@example.com if you have questions or wish to attend but did not receive the invitation.
Learn more about our disease model initiative.